Yong Yang1, Peng Zhang1, Yanfeng Zhao1, Jie Yang1, Gening Jiang1, Jie Fan1,2. 1. a Department of Thoracic Surgery , Shanghai Pulmonary Hospital, Tongji University School of Medicine , Shanghai , China. 2. b Department of Surgery , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.
Abstract
BACKGROUND: Lung cancer is the most common cancer that is caused by perturbation of regulatory pathways rather than dysfunction of a single gene. Cisplatin (CDDP; cis-diamminedichloroplatinum II) is the first member of a class of platinum-containing anti-cancer medication, which binds to DNA and triggers apoptosis. CDDP-based chemotherapy is used to treat various types of cancers. However, the efficacy of CDDP in the treatment of non-small-cell lung cancer (NSCLC) is limited by acquired drug resistance. MicroRNAs have recently emerged as key regulators of cancers, and miR-26a is one of down-regulated miRNAs in A549/CDDPres cell line. This study aimed to investigate the role of miR-26a in CDDP resistance in NSCLC as well as the underlying mechanisms. METHODS: In this study, we analyzed expressional profiles of CDDP resistance-related mRNA, miRNA, and transcription factors (TF) that regulate miRNA expression in NSCLC. A549 cells were treated with CDDP, miR-26a mimic, or miR-26a inhibitor, and followed by biological analysis including drug sensitivity assay, colony formation assay, terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling (TUNEL) assay, and cell cycle analysis. Luciferase assay was used to determine the target of miR-26a. The regulation of miR-26a in Akt pathway was measured by western blot. RESULTS: High mobility group A (HMGA) 2 was identified as the target of miR-26a. Overexpression of miR-26a in A549 cells inhibited G1-S transition, increased cell death in response to CDDP treatment, and decreased the colony formation of A549 cells. MiR-26a significantly decreased the expression of E2F1, diminished Akt phosphorylation, and downregulated Bcl2 expression. Cell growth was suppressed by inhibiting HMGA2-mediated E2F1-Akt pathway. CONCLUSION: MiR-26a is responsible for A549 cell sensitivity in the treatment of CDDP through regulating HMGA2-mediated E2F1-Akt pathway.
BACKGROUND: Lung cancer is the most common cancer that is caused by perturbation of regulatory pathways rather than dysfunction of a single gene. Cisplatin (CDDP; cis-diamminedichloroplatinum II) is the first member of a class of platinum-containing anti-cancer medication, which binds to DNA and triggers apoptosis. CDDP-based chemotherapy is used to treat various types of cancers. However, the efficacy of CDDP in the treatment of non-small-cell lung cancer (NSCLC) is limited by acquired drug resistance. MicroRNAs have recently emerged as key regulators of cancers, and miR-26a is one of down-regulated miRNAs in A549/CDDPres cell line. This study aimed to investigate the role of miR-26a in CDDP resistance in NSCLC as well as the underlying mechanisms. METHODS: In this study, we analyzed expressional profiles of CDDP resistance-related mRNA, miRNA, and transcription factors (TF) that regulate miRNA expression in NSCLC. A549 cells were treated with CDDP, miR-26a mimic, or miR-26a inhibitor, and followed by biological analysis including drug sensitivity assay, colony formation assay, terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling (TUNEL) assay, and cell cycle analysis. Luciferase assay was used to determine the target of miR-26a. The regulation of miR-26a in Akt pathway was measured by western blot. RESULTS: High mobility group A (HMGA) 2 was identified as the target of miR-26a. Overexpression of miR-26a in A549 cells inhibited G1-S transition, increased cell death in response to CDDP treatment, and decreased the colony formation of A549 cells. MiR-26a significantly decreased the expression of E2F1, diminished Akt phosphorylation, and downregulated Bcl2 expression. Cell growth was suppressed by inhibiting HMGA2-mediated E2F1-Akt pathway. CONCLUSION:MiR-26a is responsible for A549 cell sensitivity in the treatment of CDDP through regulating HMGA2-mediated E2F1-Akt pathway.
Entities:
Keywords:
Cisplatin resistance; E2F1; HMGA2; miR-26a; non-small-cell lung cancer
Authors: X Li; J Zhang; L Gao; S McClellan; M A Finan; T W Butler; L B Owen; G A Piazza; Yaguang Xi Journal: Cell Death Differ Date: 2011-10-07 Impact factor: 15.828
Authors: Monica Fedele; Rosa Visone; Ivana De Martino; Giancarlo Troncone; Dario Palmieri; Sabrina Battista; Andrea Ciarmiello; Pierlorenzo Pallante; Claudio Arra; Rosa Marina Melillo; Kristian Helin; Carlo Maria Croce; Alfredo Fusco Journal: Cancer Cell Date: 2006-06 Impact factor: 31.743
Authors: Nisha Bansal; Douglas C Marchion; Elona Bicaku; Yin Xiong; Ning Chen; Xiaomang B Stickles; Entidhar Al Sawah; Robert M Wenham; Sachin M Apte; Jesus Gonzalez-Bosquet; Patricia L Judson; Ardeshir Hakam; Johnathan M Lancaster Journal: J Gynecol Oncol Date: 2012-01-09 Impact factor: 4.401
Authors: Jianmin Wang; Antonios Papanicolau-Sengos; Sreenivasulu Chintala; Lei Wei; Biao Liu; Qiang Hu; Kiersten Marie Miles; Jeffrey M Conroy; Sean T Glenn; Manuela Costantini; Cristina Magi-Galluzzi; Sabina Signoretti; Toni Choueiri; Michele Gallucci; Steno Sentinelli; Vito M Fazio; Maria Luana Poeta; Song Liu; Carl Morrison; Roberto Pili Journal: Oncotarget Date: 2016-05-24